Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy Y.

Slides:

Advertisements

Similar presentations

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Advertisements

Manuel J. Antunes, MD, PhD, DSc

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters Victor Dayan, MD, PhD, Philippe Pibarot,

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Neovasculogenic Therapy to Augment Perfusion and Preserve Viability in Ischemic Cardiomyopathy Pavan Atluri, MD, George P. Liao, MB, Corinna M. Panlilio,

Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model Yunge Zhao, MD, PhD, Jacob.

Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac.

Changfa Guo, MD, Husnain Kh. Haider, PhD, Winston S. N

Ultrasound, endoscopy, and the recurrent nerve

Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic.

Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia Y.Joseph Woo, MD, Matthew D Taylor, BS,

Stem cell therapy in the aging hearts of Fisher 344 rats: Synergistic effects on myogenesis and angiogenesis Jiang-Yong Min, MD, Yu Chen, MD, Sohail.

Cellular coating of the left ventricular assist device textured polyurethane membrane reduces adhesion of Staphylococcus aureus Tomohiro Asai, MD, Mei-Ho.

Building a bioartificial heart: A 3-song saga

Myocardial regeneration for chronic heart failure: Not as easy as it sounds Richard A. Hopkins, MD The Journal of Thoracic and Cardiovascular Surgery

Personalized cardiac surgery: Can noninvasive flow imaging lead to individualized resection strategies for bicuspid aortopathy? Nicholas D. Andersen,

Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction J.

Intrinsic cardiac stem cells are essential for regeneration

Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure Mark F. Berry, MD, Timothy.

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function

Abracadabra I, II…HeartMate 3?

Form ever follows function

Left ventricular unloading before reperfusion reduces endothelin-1 release and calcium overload in porcine myocardial infarction Sophie Tamareille, PhD,

Victor van Berkel, MD, PhD

William M. DeCampli, MD, PhD

Left atrial endocardial dysfunction and platelet activation in patients with atrial fibrillation and mitral stenosis Zhi-Qiang Luo, MD, Xing-Hai Hao,

Daniel G. Nicastri, MD, Maoxin Wu, MD, PhD, Jaime Yun, MD, Scott J

Cardiac stem cells in the real world

The lord of the rings Antonio Miceli, MD, PhD

Jared P. Beller, MD, Irving L. Kron, MD

Arman Kilic, MD, Pavan Atluri, MD

Natural history of coexistent tricuspid regurgitation in patients with degenerative mitral valve disease: Implications for future guidelines Andrew B.

John V. Conte, MD The Journal of Thoracic and Cardiovascular Surgery

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Get it right the first time

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy Jiashing Yu,

Jennifer J. Chung, MD, Jonathan Gordon, BA, Pavan Atluri, MD

Association of electrostimulation with cell transplantation in ischemic heart disease Abdel Shafy, MD, Thomas Lavergne, MD, Christian Latremouille, MD,

Leora B. Balsam, MD, Abe DeAnda, MD

Niv Ad, MD, Lawrence M. Wei, MD

A fate worse than death Jennifer S. Lawton, MD

Cardiac myxoma: Simplifying a “complex” case

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell–derived factor 1α angiogenic therapy for acute myocardial.

Physiologic left ventricular reconstruction: Shape, function, and time recaptured Gerald D. Buckberg, MD The Journal of Thoracic and Cardiovascular Surgery

Very severe chronic ventricular tachycardia due to an aneurysm in the left main coronary artery and a giant aneurysm-related pseudoaneurysm Changfa Guo,

Jason J. Han, MD, Pavan Atluri, MD

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Pavan Atluri, MD, Corinna M. Panlilio, BA, George P. Liao, MB, Eric E

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain Subhasis.

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

The continuing challenge of congenital heart disease in China

Ascending aortitis and aortic valve endocarditis in an infant

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Why arch curvature affects arch resistance

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

First in line for robotic surgery: Would you want to know?

More than vital: Who bears the burden?

Mathematically engineered stromal cell–derived factor-1α stem cell cytokine analog enhances mechanical properties of infarcted myocardium John W. MacArthur,

Hari R. Mallidi, MD The Journal of Thoracic and Cardiovascular Surgery

Zone zero thoracic endovascular aortic repair is all about “location, location, location” Kevin L. Greason, MD The Journal of Thoracic and Cardiovascular.

Presentation transcript:

Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy Y. Joseph Woo, MD, Todd J. Grand, BS, Mark F. Berry, MD, Pavan Atluri, MD, Mireille A. Moise, MD, Vivian M. Hsu, BA, Jeffrey Cohen, Omar Fisher, BSE, Jeffrey Burdick, BS, Matthew Taylor, BS, Suzanne Zentko, MD, George Liao, MB, Max Smith, Steve Kolakowski, MD, Vasant Jayasankar, MD, Timothy J. Gardner, MD, H. Lee Sweeney, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 130, Issue 2, Pages 321-329 (August 2005) DOI: 10.1016/j.jtcvs.2004.11.041 Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 A, Graph of the mean number of CD34+/VEGFR2+ coexpressing cells per high-power field in hearts from the 4 groups. B, Representative immunostains of saline control and SDF/GM-CSF-treated hearts for CD34 (green), VEGFR2 (red; merged = orange), and DAPI nuclei (blue). The Journal of Thoracic and Cardiovascular Surgery 2005 130, 321-329DOI: (10.1016/j.jtcvs.2004.11.041) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 A, Graph of the mean number of vWF-positive blood vessels per high-powered field in each group. B, Representative images of myocardial sections depicting vWF (green)–expressing blood vessels for SDF/GM-CSF-treated and saline control animals. (Original magnification 40×.) Arrows indicate vWF-positive vessels. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 321-329DOI: (10.1016/j.jtcvs.2004.11.041) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 A, Representative hematoxylin and eosin-stained cross-sections of saline control and SDF/GM-CSF-treated hearts. Large arrows indicate where left ventricular diameter was measured, and small arrows indicate where border-zone thickness was measured. B, Graph of the mean ventricular diameter and wall thickness for each group. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 321-329DOI: (10.1016/j.jtcvs.2004.11.041) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Improved contractility was seen among SDF/GM-CSF-treated animals (slope, 1.7 ± 0.4; x-intercept, 76.2 ± 21.3 μL; r = 0.96; n = 10) when compared with control animals (slope, 0.54 ± 0.19; x-intercept, 122.1 ± 15.2 μL; r = 0.78; n = 10; P < .01). Representative pressure-volume loops for all 4 groups are displayed. The Journal of Thoracic and Cardiovascular Surgery 2005 130, 321-329DOI: (10.1016/j.jtcvs.2004.11.041) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions